Authors: Valberg Stephanie J, Schultz Abigail E, Finno Carrie J, Bellone Rebecca R, Hughes Shayne S
Journal: Journal of veterinary internal medicine
Summary
# Editorial Summary The MYH1E321G mutation in Quarter Horses and related breeds predisposes to muscle atrophy and rhabdomyolysis, yet its prevalence and triggers remain poorly characterised in clinical practice. Valberg and colleagues conducted a retrospective case-control survey of 385 Quarter Horses (275 wild-type, 100 heterozygous carriers, 10 homozygous mutants) to establish genotype-phenotype relationships and identify potential precipitants of clinical disease. Muscle atrophy was markedly dose-dependent: 80% of homozygous horses, 17% of heterozygotes, and 11% of wild-type controls reported atrophy episodes (P <0.001), with homozygous individuals exhibiting faster onset and 50% recurrence rates; critically, homozygous horses showed significantly poorer recovery prospects than heterozygotes (P <0.001). Whilst stiffness occurred across all genotypes without significant difference (40–18%), approximately 47% of affected mutant carriers had been vaccinated or suffered respiratory or gastrointestinal disease within three months preceding clinical signs, yet inciting causes remained unexplained in over half of cases. Despite atrophy burden limiting competitive participation in homozygous horses (only 4/10 competing), heterozygous carriers achieved championship-level performance, suggesting carrier status alone need not preclude athletic function—a nuance that should inform breeding decisions, pre-purchase screening protocols, and management strategies for affected individuals, particularly regarding vaccination timing and infectious disease surveillance.
Read the full abstract on PubMed
Practical Takeaways
- •Quarter Horses and related breeds carrying the MYH1E321G mutation should be identified through genetic testing, as homozygous carriers have an 80% risk of muscle atrophy that often recurs and may not fully resolve
- •Monitor for atrophy and stiffness in the 3-month period following vaccination or infectious disease in carrier horses, as these events may trigger clinical signs
- •Heterozygous carriers can achieve high performance levels including national and world championships, suggesting this genotype does not necessarily limit competitive capability
Key Findings
- •Atrophy prevalence increased with MYH1E321G mutation dosage: 80% in homozygous (My/My), 17% in heterozygous (My/N), and 11% in wild-type (N/N) Quarter Horses
- •Homozygous My/My horses experienced rapid atrophy with 50% recurrence and were less likely to recover compared to heterozygous horses
- •Vaccination or respiratory/gastrointestinal disease occurred in 47% of affected MYH1E321G horses within 3 months before atrophy/stiffness onset
- •Performance achievement did not differ significantly by genotype, though only 4 of 10 My/My horses were competing